Cellbxhealth PLC 05 November 2025 5 November 2025 CELLBXHEALTH plc ("the Company") CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conference · Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Guildford, UK and Plymouth Meeting PA, USA, - 5 November 2025 - CELLBXHEALTH plc...